Payment overview · 2025
General Payments
$681.44
43 reported records · 12 companies
Healthcare provider profile · identity verified
Gene Thomas Callais, MD
Allopathic & Osteopathic Physicians|Family Medicine · BROUSSARD, LA · NPI 1528315280
Verified facts
What the public records show
CMS Open Payments records show Gene Thomas Callais, MD received $681.44 in general payments during 2025 across 43 reported records.
Amgen Inc. accounted for 24.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $164.38 | 24.1% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $149.15 | 21.9% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $108.69 | 15.9% | 7 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $54.72 | 8.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $44.80 | 6.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $39.76 | 5.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.47 | 4.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.52 | 2.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.55 | 2.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.15 | 2.7% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.56 | 2.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $14.69 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $681.44 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $113.84 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $113.84 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $108.69 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $106.95 | 8 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $54.72 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $50.54 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.20 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $39.76 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $30.58 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.88 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.52 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $16.56 | 1 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 51 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 107 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
107 | 35 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
65 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 137 | 68 |
| Atorvastatin Calcium | Atorvastatin Calcium | 133 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 125 | 59 |
| Gabapentin | Gabapentin | 116 | 42 |
| Levothyroxine Sodium | Levothyroxine Sodium | 114 | 37 |
| Mounjaro | Tirzepatide | 107 | 35 |
| Tramadol Hcl | Tramadol Hcl | 107 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 45 |
| Amlodipine Besylate | Amlodipine Besylate | 96 | 46 |
| Metformin Hcl Er | Metformin Hcl | 90 | 38 |
| Carvedilol | Carvedilol | 71 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 68 | 21 |
| Lisinopril | Lisinopril | 68 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 29 |
| Furosemide | Furosemide | 66 | 31 |
| Ozempic | Semaglutide | 65 | 15 |
| Meloxicam | Meloxicam | 63 | 35 |
| Trazodone Hcl | Trazodone Hcl | 57 | 26 |
| Jardiance | Empagliflozin | 51 | 17 |
| Sertraline Hcl | Sertraline Hcl | 51 | 21 |
| Glipizide Er | Glipizide | 49 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 18 |
| Buspirone Hcl | Buspirone Hcl | 46 | 19 |
| Alprazolam | Alprazolam | 45 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 22 |
| Eliquis | Apixaban | 40 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 36 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | 14 |
| Alendronate Sodium | Alendronate Sodium | 37 | 11 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 37 | 14 |
| Celecoxib | Celecoxib | 35 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 33 | 17 |
| Losartan Potassium | Losartan Potassium | 32 | 17 |
| Allopurinol | Allopurinol | 30 | 11 |
| Aripiprazole | Aripiprazole | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | 15 |
| Glimepiride | Glimepiride | 29 | 11 |
| Metformin Hcl | Metformin Hcl | 29 | 12 |
| Mirtazapine | Mirtazapine | 29 | 11 |
| Omeprazole | Omeprazole | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | 18 |
| Methocarbamol | Methocarbamol | 28 | 18 |
| Montelukast Sodium | Montelukast Sodium | 26 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 23 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 22 | 12 |
| Diazepam | Diazepam | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | 11 |
| Levofloxacin | Levofloxacin | 21 | 20 |
| Potassium Chloride | Potassium Chloride | 21 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Simvastatin | Simvastatin | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 13 |
| Mupirocin | Mupirocin | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $681.44 · 43 records | Amgen Inc. | AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, ENROUTE Transcarotid Neuroprotection System, GARDASIL 9, IBSRELA, JARDIANCE, KRYSTEXXA, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, QULIPTA, REPATHA, UBRELVY, VRAYLAR, XIFAXAN, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error